# A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

> **NCT05151744** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 187 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Vamikibart
- **DRUG:** Ranibizumab
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT05151744
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2024-04-17
- **Final completion:** 2024-10-01
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05151744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05151744, "A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05151744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*